Insulet (PODD) Rating Increased to Buy at ValuEngine

ValuEngine upgraded shares of Insulet (NASDAQ:PODD) from a hold rating to a buy rating in a research report sent to investors on Monday.

PODD has been the topic of several other research reports. BidaskClub upgraded shares of Insulet from a buy rating to a strong-buy rating in a report on Friday, March 23rd. Oppenheimer set a $82.00 price objective on shares of Insulet and gave the stock a hold rating in a report on Thursday, February 22nd. Barclays restated a buy rating and set a $78.00 price objective on shares of Insulet in a report on Wednesday, December 13th. UBS upgraded shares of Insulet from a market perform rating to an outperform rating in a report on Monday, January 8th. Finally, Zacks Investment Research downgraded shares of Insulet from a hold rating to a sell rating in a report on Tuesday, January 9th. Seven analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $75.00.

How to Become a New Pot Stock Millionaire

Insulet stock opened at $86.08 on Monday. The company has a debt-to-equity ratio of 3.57, a quick ratio of 5.85 and a current ratio of 6.24. Insulet has a 12-month low of $38.43 and a 12-month high of $88.88. The firm has a market cap of $4,928.79, a P/E ratio of -187.13 and a beta of 1.38.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.04). Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The company had revenue of $130.50 million for the quarter, compared to analyst estimates of $125.16 million. During the same quarter in the previous year, the firm earned ($0.16) EPS. The firm’s revenue was up 26.0% on a year-over-year basis. equities research analysts expect that Insulet will post -0.29 EPS for the current fiscal year.

In related news, Director David A. Lemoine sold 641 shares of the stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $49,235.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Shacey Petrovic sold 1,319 shares of the stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $76.81, for a total transaction of $101,312.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,800 shares of company stock valued at $2,412,739. 1.90% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of PODD. Cerebellum GP LLC bought a new position in Insulet during the fourth quarter valued at about $122,000. Equitec Specialists LLC bought a new position in Insulet during the fourth quarter valued at about $145,000. James Hambro & Partners bought a new position in Insulet during the fourth quarter valued at about $165,000. C M Bidwell & Associates Ltd. bought a new position in Insulet during the fourth quarter valued at about $188,000. Finally, Diversified Trust Co bought a new position in Insulet during the fourth quarter valued at about $218,000.

COPYRIGHT VIOLATION WARNING: “Insulet (PODD) Rating Increased to Buy at ValuEngine” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was copied illegally and reposted in violation of US and international copyright laws. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3335311/insulet-podd-rating-increased-to-buy-at-valuengine.html.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Analysts Anticipate First Industrial Realty Trust, Inc.  Will Announce Earnings of $0.38 Per Share
Analysts Anticipate First Industrial Realty Trust, Inc. Will Announce Earnings of $0.38 Per Share
TPI Composites  Expected to Announce Earnings of $0.03 Per Share
TPI Composites Expected to Announce Earnings of $0.03 Per Share
Brokerages Expect Kinsale Capital Group  to Announce $0.36 Earnings Per Share
Brokerages Expect Kinsale Capital Group to Announce $0.36 Earnings Per Share
President Trump  Market Capitalization Reaches $0.00
President Trump Market Capitalization Reaches $0.00
EDRCoin  Tops 24 Hour Volume of $2,782.00
EDRCoin Tops 24 Hour Volume of $2,782.00
WCOIN  Price Hits $0.0991 on Exchanges
WCOIN Price Hits $0.0991 on Exchanges


© 2006-2018 Ticker Report. Google+.